fda warning letters compounded semaglutide october 2025 issued 30 to telehealth companies for false and misleading claims about GLP-1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading September 8, 2025: FDA launches

The AOAs Evidence-based Optometry Committee offers clinical recommendations for doctors of optometry

4 For comparison, metformina powerful diabetes drugtypically drops HbA1c by about 1 to 1.5%, and high-dose semaglutide (Ozempic) reduces it by about 1.5 to 1.8%

The current study involves a representative sub-cohort (including baseline visit and follow-up visits from control schools)

Insert the needle For most adults using a 46 mm needle, insert at 90 degrees

Insufficient safety data

GLP-1 medications can help manage type 2 diabetes and obesity, but they may cause short-term mild-to-moderate side effects such as nausea, vomiting, diarrhoea, constipation, bloating, and decreased appetite, particularly at the beginning of treatment